UK ENcorafenib and BInimetinib Real-world Study in Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrew Furness, MBBS, MRCP, PhD
Royal Marsden NHS Foundation Trust
Principal Investigator - Tarandeep Singh Matharu, MPharm, PgCert
Pierre Fabre Limited
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Southend University Hospital
Westcliff-on-Sea, Essex, United Kingdom
- Queen Elizabeth Hospital
Birmingham, United Kingdom
- Addenbrookes Hospital
Cambridge, United Kingdom
- University Hospital Coventry and Warwickshire
Coventry, United Kingdom
- Royal Marsden Hospital
London, United Kingdom
- Royal Preston Hospital
Preston, United Kingdom
- Southampton General Hospital
Southampton, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2025
- Primary completion
- 13 Jan 2028
- Completion
- 13 Jan 2028
- Last update posted
- 13 Apr 2026
- Registered enrollment
- 50
- Registry id
- NCT07022457
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.